In Week of Mar 28, 2026, SMS Pharmaceuticals Ltd (Pharma - API & CRAMS) is outperforming Nifty 500 with +37.7% relative strength. Fundamentals: Average. On a 12-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Achieving target integration level by March 2026 to stabilize margins at 20%+
Impact: +₹17.5 Cr revenue
“Vamsi Krishna Potluri: 'We will be achieving around 80% to 85% in this coming year, that's the target.'”
What: Return of tender-based ARV business to historical contribution levels
Impact: +₹27.5 Cr revenue
“Vamsi Krishna Potluri: 'But we are expecting may be next year I think could be around 12%-15% contribution.'”
Earnings deceleration risks from management commentary
Trigger: Unfavorable tender outcomes
Impact: -300 bps margin impact
Management view: Company demonstrated ability to replace lost ARV revenue with other segments like anti-diabetic APIs.
Monitor: ARV segment contribution percentage
Trigger: Pricing pressure or demand slowdown in anti-diabetic APIs
Impact: -250 bps margin impact
Management view: No direct response to concentration risk question in transcript
Monitor: Anti-diabetic segment revenue share
Key quotes from recent conference calls
“We will be achieving around 80% to 85% [backward integration] in this coming year, that's the target. — Vamsi Krishna Potluri”
“The profitability definitely depends on the product mix very much because there could be a few quarters where a low market products would be going good in the number of sales. But I think going forward, I think the main target of us is to manufacture our own products and have — be more vertically dependent, vertically integrated and have a control on the input costs, so that we have the raw material costs in our control. — Vamsi Krishna Potluri”
“Definitely, I think anti-viral will come back, definitely we will be and that will be additional revenue for the company. — Vamsi Krishna Potluri”
“The outlook remains positive, and the company is on-track to achieve its pre-COVID growth numbers. — Management”
Forward-looking targets from management for Next 2-4 quarters
Implied PAT Growth
25%
OPM Guidance
20%
Key Milestones
• 80-85% backward integration by March 2026
• ARV segment recovery to 12-15% in FY27
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +21% | +15% | Stable |
| PAT (Net Profit) | +28% | +4% | Stable |
| OPM | 21.0% | +200 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
SMS Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
SMS Pharmaceuticals Ltd's profit is growing with an stable trend.
SMS Pharmaceuticals Ltd's revenue growth trend is stable.
SMS Pharmaceuticals Ltd's operating margin is volatile.
SMS Pharmaceuticals Ltd's long-term compounding rates
SMS Pharmaceuticals Ltd's earnings growth is stable with mixed signals on a sequential basis.
SMS Pharmaceuticals Ltd's trailing twelve month (TTM) performance
SMS Pharmaceuticals Ltd appears significantly overvalued based on our fair value analysis.
SMS Pharmaceuticals Ltd's current PE ratio is 40.4x.
SMS Pharmaceuticals Ltd's current PE is 40.4x.
SMS Pharmaceuticals Ltd's price-to-book ratio is 5.0x.
SMS Pharmaceuticals Ltd is rated Average with a fundamental score of 40.2/100. This score is calculated from objective financial metrics
SMS Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
SMS Pharmaceuticals Ltd's return ratios over recent years
SMS Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
SMS Pharmaceuticals Ltd's current dividend yield is 0.10%.
SMS Pharmaceuticals Ltd's shareholding pattern (Dec 2025)
SMS Pharmaceuticals Ltd's promoter holding has remained stable recently.
SMS Pharmaceuticals Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
SMS Pharmaceuticals Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
SMS Pharmaceuticals Ltd has 2 key growth catalysts identified from recent earnings analysis
SMS Pharmaceuticals Ltd has 2 key risks worth monitoring
In Q3 FY26, SMS Pharmaceuticals Ltd's management highlighted
SMS Pharmaceuticals Ltd's management has provided the following forward guidance for Next 2-4 quarters
Based on quantitative research signals, here is why SMS Pharmaceuticals Ltd may be worth studying
SMS Pharmaceuticals Ltd investment thesis summary:
SMS Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
